NuCana plc has initiated an expansion study of its anti-cancer drug NUC-7738 combined with pembrolizumab for patients with melanoma resistant to PD-1 inhibitors, with initial data expected in Q4 2025 ...
Icon Plc ((ICLR)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results